Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: Results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials

H. M. Earl*, L. Hiller, J. A. Dunn, A. L. Vallier, S. J. Bowden, S. D. Jordan, F. Blows, A. Munro, S. Bathers, R. Grieve, D. A. Spooner, R. Agrawal, I. Fernando, A. M. Brunt, S. M. O'Reilly, S. M. Crawford, Daniel Rea, P. Simmonds, J. L. Mansi, A. StanleyK. McAdam, L. Foster, R. Cf Leonard, C. J. Twelves, D. Cameron, J. Ms Bartlett, P. Pharoah, E. Provenzano, C. Caldas, C. J. Poole

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

11 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: Results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials'. Together they form a unique fingerprint.

Medicine & Life Sciences